Vical presents Allovectin-7 data

In one Phase I and two Phase II studies in a total of 60 HLA-B7-negative patients with advanced head and neck cancer, 6 clinical responses and 14 cases of stable disease were seen with one Allovectin-7 treatment cycle. These 20 patients then received a second therapy cycle, which gave 5 partial responses ranging from 20-79 weeks and 6 cases of stable disease ranging from 18-34 weeks. No serious treatment-related side effects were noted. Data were presented at the Head & Neck Cancer Conference in San Francisco. Allovectin-7 is a gene encoding HLA-B7 mismatched transplantation antigen complexed with lipid. ...